Position in ERAS
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$22,848,758
+$11,631,019 QoQ
Shares Held
1,247,203
+79.9% QoQ
Ownership
0.357%
of shares outstanding
% of Portfolio
0.04%
of 13F equity value
Holder Rank
#41
of 257 holders
Holding Since
Mar 2023
7 quarters on record
Voting authority
Sole 0%
Shared 100%
None 0%
Common Shares in ERAS Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Point72 Asset Management, L.P. holds $2,243,273,342 across 172 Biotechnology names. ERAS ranks #29 (1.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ROIV |
Roivant Sciences Ltd.
|
4,473,478 | $158,316,386 | |
| 2 | CYTK |
Cytokinetics Inc
|
1,587,712 | $135,257,185 | |
| 3 | BBIO |
BridgeBio Pharma, Inc.
|
1,525,782 | $113,640,243 | |
| 4 | AXSM |
Axsome Therapeutics, Inc.
|
416,516 | $101,950,621 | |
| 5 | LEGN |
Legend Biotech Corp
|
3,076,124 | $88,838,461 | |
| 6 | MDGL |
Madrigal Pharmaceuticals, Inc.
|
137,029 | $73,577,721 | |
| 7 | CELC |
Celcuity Inc.
|
650,916 | $68,098,831 | |
| 8 | ACAD |
Acadia Pharmaceuticals Inc
|
2,433,168 | $61,559,150 |
All Filings in ERAS
Export CSV
7 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $22,848,758 | 1,247,203 | Shares | Defined | 2026-08-14 | |
| 2026-03-31 | $11,217,739 | 693,309 | Shares | Defined | 2026-05-15 | |
| 2025-03-31 | $55,515 | 40,522 | Shares | Defined | 2025-07-21 | |
| 2024-09-30 | $173,625 | 63,599 | Shares | Defined | 2024-11-14 | |
| 2024-06-30 | $2,443,135 | 1,035,227 | Shares | Defined | 2024-09-16 | |
| 2024-03-31 | $2,258,283 | 1,096,254 | Shares | Defined | 2024-05-15 | |
| 2023-03-31 | $106,848 | 35,498 | Shares | Defined | 2023-05-15 | |
| No filing history on record for this holder in this stock. | ||||||